Evaluating the therapeutic efficacy of Habb-e-Ghafis in Non-alcoholic fatty liver disease, a randomised, single blind, standard controlled trial

Central Council for Research in Unani Medicine New Dehli0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年2月21日

研究概览

暂无简介。

•1. Ultrasonography (USG) documented grade 1 (mild) and grade 2 (moderate) non-alcoholic fatty liver disease.
•2. Patients with dull ache/heaviness in the right hypochondriac region.
•3. Patients irrespective of gender.
•4. Patients in the age group of 20 to 60.
•5. Body Mass Index (BMI) < 35 kg/m2.
•6. Patients willing to sign written informed consent.

•1. Patients below the age of 20 years and above 60 years.
•2. Grade 3 fatty liver or above.
•3. Prior diagnosis of chronic liver disease other than NAFLD including autoimmune, viral and alcoholic liver disease.
•4. Patients having fulminant hepatitis and drug induced hepatitis.
•5. Prior diagnosis of liver cirrhosis.
•6. History of liver transplantation.
•7. Body Mass Index (BMI) > 35kg/m2
•8. Pregnant or breastfeeding mothers.
•9. Active case of malignancy.
•10. Patients having cholelithiasis or cholecystitis.
•11. Patients having Diabetes Mellitus.
•12. Patients with cardiovascular or renal diseases.
•13. Unwillingness or inability to fulfill the protocol.
•14. Patients who fail to give consent.

发起方

Central Council for Research in Unani Medicine New Dehli